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Objective
To assess OnabotulinumtoxinA safety and efficacy in
prophylactic treatment for chronic refractory migraine
(headache occurring at least 15 days per month with lack
of responsiveness to at least two preventive medications
with established efficacy) [1] with associated fatigue
symptom.
Methods
From March 2014 to May 2015 patients meeting the clini-
cal diagnostic criteria for chronic refractory migraine were
enrolled. Patients were treated with OnabotulinumtoxinA
every three months according to the standard procedure
(155-195 units) [2]. At baseline (T0) and after 6 months,
at the third treatment (T1), a structured questionnaire was
administered, including: a) migraine features [frequency
(headache days/month), pain severity (Verbal Numeric
Scale, VNS), acute medicines consumption/month, disabil-
ity (Headache Impact Test, HIT-6), ictal cutaneous allody-
nia (Allodynia Symptoms Check-list 12, ASC-12)]; b)
associated symptoms [fatigue (Fatigue Severity Scale, FSS),
anxiety symptoms (Generalized Anxiety Disorder, GAD-
7), depressive symptoms (Patient Health Questionnaire,
PHQ-9)]. Wilcoxon test was performed for the T0-T1
comparisons.
Results
Twenty-one patients were enrolled (M/F=3/18; mean age:
52.6±9.71). A patient discontinued the study after the first
treatment due to an adverse event (eyelid ptosis). Twenty
patients were evaluated at T1, with migraine features
changing as follow: T0 frequency Me=30 IQR=10, T1 fre-
quency Me=13 IQR=13, T0 VNS Me=8 IQR=3, T1 VNS
Me=8 IQR=4, T0 acute medicines consumption/month
Me=20 IQR=15, T1 acute medicines consumption/month
Me=7 IQR=13, T0 HIT-6 Me=66 IQR=7, T1 HIT-6
Me=63 IQR=13, T0 ASC-12 Me=8 IQR=5, T1 ASC-12
Me=6 IQR=7. Associated symptoms changed as follow: T0
FSS Me=48 IQR=19, T1 FSS Me=33 IQR=23, T0 GAD-7
Me=10 IQR=8, T1 GAD-7 Me=9 IQR=7, T0 PHQ-9
Me=10 IQR=11, T1 PHQ-9 Me=7 IQR=7. After two injec-
tion cycles with OnabotulinumtoxinA, a statistically signif-
icant reduction was found in: a) frequency (p = 0.001; r =
0.51); b) acute medicines consumption/month (p = 0.001;
r = 0.54); c) FSS score (p = 0.009; r = 0.41).
Conclusions
OnabotulinumtoxinA resulted well tolerated and effective
in reducing not only frequency and acute medication use,
but also fatigue in our population of chronic refractory
migraineurs.
Written informed consent to publication was obtained
from the patient(s).
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